RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
RHYTHM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$88.23+2.06 (+2.39%)
Close on Oct 19, 2026
- Market cap
- $6.05B
- P/E (TTM)
- –
- Dividend yield
- –
RHYTHM PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $71.26M | $60.11M | $57.25M | $51.30M | $48.50M | $37.72M | $41.83M | $33.25M | $29.08M | $25.97M | $24.23M | $22.50M | 100.0% | +46.9% |
| License revenue | $0 | $0 | $0 | $0 | $0 | -$5.01M | – | – | – | – | – | – | 0.0% | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | $31.67M | $23.30M | – | – | $18.34M | $17.94M | – | – |
| Germany | – | – | – | – | – | – | – | $3.62M | – | – | $2.79M | $1.91M | – | – |
| Other | – | – | – | – | – | – | – | $6.33M | – | – | $3.10M | $2.66M | – | – |
From the segment and revenue-disaggregation notes of Rhythm Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.